Circulating tumor cells in metastatic colorectal cancer: Efficacy and feasibility of different enrichment methods

Robert Königsberg(Kaiser-Franz-Josef-Spital), Robert Zeillinger(Comprehensive Cancer Center Vienna), Daniela Jahn-Kuch(Kaiser-Franz-Josef-Spital), Marcus Hudec(University of Vienna), Georg Pfeiler(Medical University of Vienna), Christian Dittrich(Leibniz Institute for Agricultural Engineering and Bioeconomy), Gudrun Hager(Medical University of Vienna), Margit Gneist(Kaiser-Franz-Josef-Spital)

Cancer Letters

February 19, 2010

10.1016/j.canlet.2010.01.003

Cited by 53

Related Papers

Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization

|Blood|2000|322

Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study

|The Lancet Oncology|2021|255

Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients

|Acta Oncologica|2011|239

Phase II Study of Imatinib in Patients With Recurrent Gliomas of Various Histologies: A European Organisation for Research and Treatment of Cancer Brain Tumor Group Study

|Journal of Clinical Oncology|2008|226

Impact of Body Mass Index on the Efficacy of Endocrine Therapy in Premenopausal Patients With Breast Cancer: An Analysis of the Prospective ABCSG-12 Trial

|Journal of Clinical Oncology|2011|222